Neogenomics INC 8-K filings

NASDAQ

26 Feb 2024

NEO

8-K/A: NeoGenomics Adopts New Performance-Based Equity Award Agreement

NeoGenomics has approved a new form of equity award agreement for performance-based restricted stock units (PSUs) under its 2023 Equity Incentive Plan.

NASDAQ

23 Feb 2024

NEO

Neogenomics INC

8-K: NeoGenomics Adopts New Performance-Based Equity Award Agreement

NeoGenomics has approved a new form of equity award agreement for performance-based restricted stock units (PSUs) under its 2023 Equity Incentive Plan.

NASDAQ

20 Feb 2024

NEO

Neogenomics INC

8-K: NeoGenomics Reports Strong Q4 and Full Year 2023 Results, Revenue Up 16%

NeoGenomics' fourth quarter revenue increased by 12% to $156 million, and full year revenue rose by 16% to $592 million, driven by growth in clinical services.